OVERVIEW

At YNIOS PHARMA, we are driven by a singular mission: to transform the landscape of critical care by addressing the devastating effects of ischemia/reperfusion injuries. Our company was born out of a deep commitment to improving outcomes for patients in life-threatening conditions where time and precision are crucial.

OUR VISION

Our vision is to be at the forefront of critical care innovation, providing healthcare professionals with the tools they need to save lives and improve recovery outcomes. We are committed to advancing medical science and delivering solutions that not only treat but also prevent the severe complications associated with ischemia/reperfusion injuries.

OUR STORY

YNIOS PHARMA began with a clear purpose—harnessing cutting-edge research to solve one of the most challenging problems in intensive care medicine. The founders recognized a critical gap in the treatment of conditions where the restoration of blood flow after an interruption can lead to significant tissue damage, organ failure, and high mortality rates. With a shared passion for scientific innovation and patient care, they embarked on a journey to develop a novel therapeutic approach that could redefine critical care practices.

OUR TEAM

YNIOS PHARMA is led by co-founders Philippe Van Wesepoel and Jean François Plucker, who bring a unique combination of skills and experience to the company.

Philippe, with his expertise in cellular physiology and the pharmaceutical industry, focuses on the development of effective treatments that restore the innate immune capacity of cells.

Jean François has a strong background in technology transfer and intellectual property management, having worked extensively on international projects that bridge the gap between scientific innovation and commercial application.

Together with their research team, they bring a wealth of knowledge, experience, and a shared vision for transforming critical care treatment. Their commitment to understanding the intricate mechanisms of cellular injury and repair drives the development of innovative solutions that address the complex challenges faced in critical care settings.

OUR COMMITMENT

We are committed to rigorous scientific research, ethical practices, and the relentless pursuit of innovation. As we advance through our clinical development phases, we remain focused on our ultimate goal: to bring TA64 to the bedside, where it can make a tangible difference in the lives of patients facing critical health challenges.

At YNIOS PHARMA, we believe that by advancing science, we advance care. We invite you to join us on this journey towards a new era in critical care medicine.